Alipogene tiparvovec
id:
alipogene-tiparvovec-257-14535796
title:
Alipogene tiparvovec
text:
Alipogene tiparvovec, sold under the brand name Glybera, is a gene therapy treatment designed to reverse lipoprotein lipase deficiency (LPLD), a rare recessive disorder, due to mutations in LPL, which can cause severe pancreatitis. It was recommended for approval by the European Medicines Agency in July 2012, and approved by the European Commission in November of the same year. It was the first marketing authorisation for a gene therapy treatment in either the European Union or the United States
brand slug:
wiki
category slug:
encyclopedia
description:
original url:
https://en.wikipedia.org/wiki/Alipogene_tiparvovec
date created:
date modified:
2024-02-20T04:51:15Z
main entity:
{"identifier":"Q5572516","url":"https://www.wikidata.org/entity/Q5572516"}
image:
{"content_url":"https://upload.wikimedia.org/wikipedia/commons/9/99/AAV_Gene_Therapy.jpg","width":495,"height":371}
fields total:
13
integrity:
14